ArticleMolecules (Basel, Switzerland)2024
Quinoxaline 1,4-di-
Isidro Palos, Alonzo González-González, Alma D Paz-González, José C Espinoza-Hicks, Debasish Bandyopadhyay, Norma Paniagua-Castro, Marlene S Galeana-Salazar, Jorge Ismael Castañeda-Sánchez, Julieta Luna-Herrera, Gildardo Rivera
Abstract read
In one paragraphArticle in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Isidro PalosUnidad Académica Multidisciplinaria Reynosa-Rodhe, Universidad Autónoma de Tamaulipas, Reynosa 88779, México.ORCID 0000-0003-0124-531X Alonzo González-GonzálezLaboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Boulevard del Maestro, s/n, Esq. Elías Piña, Reynosa 88710, México.
Alma D Paz-GonzálezLaboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Boulevard del Maestro, s/n, Esq. Elías Piña, Reynosa 88710, México.
José C Espinoza-HicksFacultad de Ciencias Químicas, Universidad Autónoma de Chihuahua, Circuito Universitario S/N, Chihuahua 31125, México.
Debasish BandyopadhyaySchool of Biological and Chemical Sciences (SIBCS), The University of Texas Rio Grande Valley, 1201 West University Drive, Edinburg, TX 78539, USA.ORCID 0000-0002-2726-5127 Norma Paniagua-CastroDepartamento de Fisiología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, México.
Marlene S Galeana-SalazarDepartamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Ciudad de México 09460, México.
Jorge Ismael Castañeda-SánchezDepartamento de Sistemas Biológicos, Universidad Autónoma Metropolitana-Xochimilco, Ciudad de México 09460, México.ORCID 0000-0002-4323-4988 Julieta Luna-HerreraDepartamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Ciudad de México 11340, México.
Gildardo RiveraLaboratorio de Biotecnología Farmacéutica, Centro de Biotecnología Genómica, Instituto Politécnico Nacional, Boulevard del Maestro, s/n, Esq. Elías Piña, Reynosa 88710, México.ORCID 0000-0001-9842-4167 Funding
Secretaria de Investigacion y Posgrado del Instituto Politecnico Nacional 20230935 and 20240460
6 · The paper itselfAbstract
Mycetoma is currently considered as a neglected tropical disease. The incidence of mycetoma is unknown but most of the worldwide cases are present in the "mycetoma belt" including countries like Mexico, India, Senegal, and others. The treatment of mycetoma depends on the etiological agent responsible for the case. Treatment success reaches 60 to 90%; however, common treatment has been reported to be ineffective in some cases, due in part to resistance to the prescribed antibiotics. Therefore, it is necessary to develop new therapeutic options. In the past two decades, quinoxaline derivatives have shown relevance as antibacterial agents. Therefore, in this work, esters of quinoxaline 1,4-di-
Indexed as
Microbial Sensitivity TestsQuinoxalinesAnimalsCell LineHumansMacrophagesMiceMolecular StructureQuinoxalinesantibacterialdrugsNocardiaquinoxaline 1,4-di-N-oxidescaffold
Identifiers
PMID39407582
PMCPMC11478375
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390